Can gut-restricted PDE4 inhibitors transform treatment for ulcerative colitis and Crohn’s?
Palisade Bio’s PALI-2108 secures a Japanese patent. Explore how this gut-targeted PDE4 inhibitor could change the game in ulcerative colitis and Crohn’s.
Pharma & Biotech
Pharma & Biotech
Enveda’s ENV-6946 enters Phase 1: Can a “multi-biologic in a pill” reshape the future of IBD therapy?
Can Enveda’s ENV-6946 deliver the efficacy of biologics in a pill for IBD? Find out why its triple-cytokine Phase 1 trial is drawing industry attention.
Pharma & Biotech
Can Gotenfia finally unlock biosimilar competition for Simponi in Europe?
STADA Arzneimittel AG and Bio-Thera Solutions have secured a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Gotenfia, a proposed biosimilar to the tumor necrosis factor alpha inhibitor golimumab. The product references Simponi, an originator drug widely prescribed for multiple autoimmune conditions. If approved, Gotenfia would be marketed